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Abstract
Introduction: Osteoporosis is one of the commonest metabolic diseases of bone. Its possible causes may include thyroid hormonal dys-
function. The objective of this study was to evaluate the effects of hyperthyroidism and hypothyroidism on osseous tissue metabolism in 
premenopausal women.
Material and methods: 38 women with hyperthyroidism, 40 with hypothyroidism and 41 healthy women participated in this study. Initially 
after 6 and 12 months, each patient underwent selected hormonal, immunological and biochemical tests, measurement of concentrations 
of bone turnover markers and densitometry were also performed. 
Results: On initial evaluation, lower cortical bone density was found in patients with hyperthyroidism (femoral neck). After 12 months, an 
increase in BMD was seen, but it was still lower than in the control group. Statistically significantly higher concentrations of bone turnover 
markers, decreasing from the sixth month of treatment, were noted only in the group with hyperthyroidism. Statistically significant dif-
ferences were not noted in the femoral neck nor in the lumbar spine BMD in patients with hypothyroidism. 
Conclusions: Hyperthyroidism poses a negative effect on bone metabolism. Hypothyroidism in premenopausal females does not have 
any influence on bone density. (Endokrynol Pol 2013; 64 (1): 40–44)
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Streszczenie 
Wstęp: Osteoporoza należy do najczęstszych chorób metabolicznych kości. Jej przyczynami mogą być między innymi choroby gruczołu 
tarczowego. Celem pracy była ocena wpływu nadczynności i niedoczynności tarczycy na metabolizm tkanki kostnej u kobiet w okresie 
przedmenopauzalnym. 
Materiał i metody: Badaniem objęto 38 kobiet z nadczynnością tarczycy, 40 — z niedoczynnością tarczycy i 41 zdrowych kobiet. Oceniano 
wyjściowo, po 6 i 12 miesiącach wybrane parametry hormonalne, immunologiczne i biochemiczne, stężenie markerów obrotu kostnego 
oraz wykonano badanie densytometryczne kości. 
Wyniki: W grupie z nadczynnością tarczycy stwierdzono obniżenie BMD w zakresie kości korowej (szyjka kości udowej). Po rocznym 
leczeniu tyreostatykiem obserwowano wzrost BMD, ale była ona nadal mniejsza niż w grupie kontrolnej. Tylko w grupie z nadczynno-
ścią tarczycy wykazano statystycznie istotnie większe stężenie markerów obrotu kostnego, które w sposób istotny zmniejszało się od 
6 miesiąca leczenia. W grupie z niedoczynnością tarczycy nie wykazano wpływu na BMD zarówno w zakresie szyjki kości udowej, jak 
i kręgosłupa lędźwiowego. 
Wnioski: Niekorzystny wpływ na metabolizm kostny wywiera nadczynność tarczycy. Niedoczynność tarczycy u kobiet przed menopauzą 
nie wpływa na gęstość kości. (Endokrynol Pol 2013; 64 (1): 40–44)
Słowa kluczowe: nadczynność tarczycy, niedoczynność tarczycy, gęstość mineralna kości (BMD), osteokalcyna (OC), C-końcowe telopeptydy 
prokolagenu typu 1 (CTx)
Introduction
Bone is a very metabolically active tissue: the processes 
of bone resorption and formation last throughout life. 
Osteoporosis is a systemic disease of the skeleton in 
which reduced bone mineral density and deterioration 
of microarchitecture lead to an increased risk of fractures 
[1, 2]. Osteoporosis is one of the commonest metabolic 
bone diseases, and it can be classified as primary or 
secondary. Primary osteoporosis is most common in 
women after the menopause, whereas secondary osteo-
porosis may arise at any age and can be caused by for 
example endocrinopathies, including hormonal thyroid 
dysfunction [3–5].
Hyper- and hypothyroidism are the commonest 
pathologies encountered in everyday endocrinological 
practice. Thyroid hormones exhibit pleiotropic effects 
in the human body which are also observed in osseous 
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tissue. Thus, any excess or deficiency of thyroxin (fT4) 
and triiodothyronine (fT3) potentially poses a risk to 
bones [6–8]. 
The objective of our study was to evaluate the ef-
fects of hyper- and hypothyroidism on osseous tissue 
metabolism (bone mineral density and selected bone 
turnover markers) at the time of diagnosis of thyroid 
dysfunction as well as after six and 12 months of treat-
ment (evaluation of potential for reversibility of meta-
bolic bone dysfunction after reaching euthyroidism) in 
premenopausal women. 
Material and methods
A total of 119 women aged 18 to 52 years participated 
in this study. They were divided into three groups. The 
first group comprised 38 women aged 22 to 52 years 
(average age 34.73 ± 7.77) with newly diagnosed hy-
perthyroidism; the second group was composed of 40 
women aged 18 to 51 years (average age 33.37 ± 10.83) 
with newly diagnosed hypothyroidism; and the third 
group (the control group) was made up of 41 healthy 
women aged 18 to 50 (average age 34.43 ± 10.12). 
For the purposes of this study, only female patients 
without previous thyroid disease history were qualified, 
prior to initiating pharmacological treatment. The study 
was approved by the Bioethics Committee in Wroclaw. 
All patients enrolled in the study were provided with 
written information on the purpose and design of the 
study. 
Patients were followed-up for a period of 12 months. 
Diagnostics studies were started during the winter (No-
vember to April). Subsequently, two control visits were 
conducted: on average after six months (i.e. between 
June and September) as well as 12 months after reach-
ing euthyroidism (i.e. between the following November 
and April). 
After initial qualification to the study (written sur-
vey, medical history and physical examination), each 
patient underwent a panel of diagnostic tests: hormonal 
(concentration of thyroid-stimulating hormone — TSH, 
free triiodothyronine — fT3, free thyroxine — fT4, para-
thyroid hormone — PTH, follicle-stimulating hormone 
— FSH, luteinising hormone — LH, oestradiol — E2, 
and testosterone), biochemical (concentration of total 
calcium, inorganic phosphates, magnesium, alkaline 
phosphatase activity), immunological (levels of antithy-
roglobulin — ATG, anti-thyroid peroxidase — ATPO, 
anti-TSH receptor antibodies — TRAB), concentration of 
markers of bone resorption (collagen type 1 crosslinked 
C-telopeptides — CTx) as well as osteogenesis (osteo-
calcin — OC); visual studies: ultrasonographic thyroid 
study, femoral neck and lumbar spine densitometry 
(to evaluate BMD among premenopausal women, the 
Z-score index was chosen). 
Six and 12 months after reaching euthyroidism, the 
above mentioned hormonal, biochemical, and immu-
nological studies and the measurement of markers of 
bone turnover concentration were repeated on every 
patient from the group under investigation. In the con-
trol group, the measurement of bone turnover markers 
concentration was performed. 
All patients with hyperthyroidism were treated with 
an oral thyrostatic — methimazole (dose from 60 to 5 mg 
per day) for the whole 12 months of the study; women 
from the group with hypothyroidism were treated with 
levothyroxine (dose from 25 to 150 ug per day). 
The results were presented in an average form in 
sample and standard deviation in sample using the 
Tukey and Welch tests; to assess for correlation, a Spear-
man test was employed. Calculations and tests were 
conducted using the SAS version 9.1 statistical pack. 
Results
On initial evaluation, a statistically significant lower 
femoral neck bone density expressed by the Z-score 
was found in female patients with hyperthyroidism 
compared to those with hypothyroidism. Statistically 
significant differences were not noted in the femoral 
neck BMD expressed in g/cm2 nor in the lumbar spine 
BMD between the studied groups. Statistically signifi-
cant higher serum concentrations of OC and CTx were 
noted in the group of females with hyperthyroidism 
than in the control group and in the group with hy-
pothyroidism. 
After 6 months of treatment, in the female patients 
treated due to hyperthyroidism, a statistically significant 
higher concentration of OC (versus hypothyroidism and 
control groups) and of CTx (versus control group) was 
demonstrated. In this group a statistically significant 
decrease in concentration of CTx was also seen. 
After 12 months of treatment, a continuing statisti-
cally significant lower femoral neck bone density ex-
pressed through Z-score index was observed in women 
from the group with hyperthyroidism compared to the 
control group (p = 0.0379), but a statistically significant 
increase in the femoral neck (p = 0.0021) and lumbar 
spine (p = 0.0001) BMD expressed in g/cm2 was seen. 
However, no statistically significant difference was 
noted in the bone density expressed through the Z-score 
in the mentioned location of the skeleton (p = 0.0021 
and p = 0.0001), compared to the initial value and after 
12 months of anti-thyroid therapy. 
In the group with hypothyroidism, no statistically 
significant difference was found between the femoral 
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neck and lumbar spine BMD as expressed through 
g/cm2 (p = 0.9903 and p = 0.5638) and Z-score (p = 
0.4303 and p = 0.4787) (Fig. 1, 2). 
In the group with hyperthyroidism, a statistically 
significant decrease in OC and CTx concentration was 
observed. In the group of females treated due to hy-
pothyroidism, no statistically significant difference in 
the concentration of markers of bone turnover before 
initiating the treatment and after 12 months of therapy 
with levothyroxine was seen (Fig. 3, 4). 
Discussion
In this study, we assessed BMD changes among patients 
with hyperthyroidism and hypothyroidism before and 
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Figure 1. Changes of femoral neck (FN) and lumbar spine (LS) 
BMD (g/cm2) among the studied groups in the one year observation 
period. *p = 0.0021 within group with hyperthyroidism; #p = 
0.0001 within group with hyperthyroidism
Rycina 1. Zmiany w gęstości kości wyrażonej w g/cm2 w zakresie 
szyjki kości udowej (FN) oraz lędźwiowego odcinka kręgosłupa 
(LS) w badanych grupach w obserwacji rocznej
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Figure 2. Changes of femoral neck (FN) and lumbar spine (LS) 
Z-score among the studied groups in the one year observation 
period
Rycina 2. Zmiany w gęstości kości wyrażonej jako wskaźnik 
Z-score w zakresie szyjki kości udowej (FN) oraz lędźwiowego 
odcinka kręgosłupa (LS) w badanych grupach w obserwacji rocznej
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Figure 3. Changes in serum concentrations of osteocalcin (OC) 
among the studied groups in the one year observation period
Rycina 3. Zmienność stężenia osteokalcyny (OC) w surowicy 
w badanych grupach w obserwacji rocznej
Figure 4. Changes in serum concentrations of collagen type 1 
crosslinked C-telopeptides (CTx) among the studied groups in the 
one year observation period
Rycina 4. Zmienność stężenia C-końcowych telopeptydów 
prokolagenu typu 1 (CTx) w surowicy w badanych grupach 
w obserwacji rocznej
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after reaching normal thyroid function compared to 
a control group. We estimated Z-score index as a point 
of reference to assess bone mineral density. A decrease 
in the BMD occurred in cortical bone (femoral neck) in 
the group with hyperthyroidism. No trabecular bone 
(lumbar spine) loss was seen in this group and this 
agrees with previously published data [9–11]. Overt 
hyperthyroidism in adults leads to shortening of the 
cycle of bone remodelling by as much as 50% and to 
disturbance of the proportions of bone formation and 
resorption processes [12], which can cause the loss 
of more than 10% of mineral bone for one cycle [4], 
and increase the risk of fractures [9, 10, 12]. After one 
year of anti-thyroid treatment, a continuing statisti-
cally significant lower femoral neck BMD expressed 
through Z-score index was observed in the group with 
hyperthyroidism compared to the control group. But 
a statistically significant increase in the femoral neck and 
lumbar spine BMD expressed in g/cm2 was noted in this 
group. There was no statistically significant difference 
in BMD expressed through Z-score comparing initial 
parameters and after 12 months of treatment. 
These results showed that after one year of antithy-
roid treatment an increase in BMD was seen, but BMD 
was still lower than in the control group. This means 
that reaching euthyroidism does not fully normalise 
bone density, at least in a one year observation period. 
Then in the group with hypothyroidism, no statisti-
cally significant changes in femoral neck and lumbar 
spine BMD (expressed in g/cm2 nor through Z-score) 
were seen after one year of levothyroxine replacement. 
According to the literature, hypothyroidism leads to 
a distinct drop of the rate of bone turnover: the pro-
cesses of bone formation become about 50%, and of 
bone resorption about 40%, slower compared to the 
bone turnover observed during a state of euthyroidism 
[12]. The influence of the lack of free thyroid hormones 
on BMD is a matter of dispute [9, 12–14]. However, hy-
pothyroidism is connected with higher fractures risk, 
although the mechanism remains unknown [15]. In our 
study, hypothyroidism had no influence on the BMD 
of studied women. 
The assessment of bone turnover markers concen-
tration is an additional and complementary to den-
sitometry method which enables us to estimate bone 
tissue metabolism. Bone turnover markers allow us to 
define the level of intensity of catabolic and anabolic 
processes in osseous tissue, and enable us to perform a 
current estimation of the skeleton’s state because their 
concentrations in blood serum change faster than BMD. 
In this study, we assessed the concentration of 
one bone formation marker (osteocalcin) and one 
bone resorption marker (collagen type 1 crosslinked 
C-telopeptides). Initially, the concentrations of OC and 
CTx were significantly higher in women with hyper-
thyroidism (versus the control group and the group 
with hypothyroidism), although there was no statisti-
cally significant difference in bone turnover markers 
concentration between the group with hypothyroidism 
and the control group. 
These results are consistent with published data 
describing enhanced bone metabolism among patients 
with hyperthyroidism [16–18]. In thyrotoxicosis, we 
observe high bone turnover, increased concentration 
of bone formation, and resorption markers and distur-
bance of mineral homeostasis, which can have a nega-
tive influence on bone mineral density. 
After six months of anti-thyroid treatment, the 
concentration of OC was still statistically significantly 
higher in women treated due to hyperthyroidism (ver-
sus the hypothyroidism and control groups). However, 
there was no statistically significant difference in OC 
concentrations between women with hypothyroidism 
and the control group. A statistically significant higher 
concentration of CTx and statistically significant de-
crease in its concentration was observed in the group 
with hyperthyroidism after six months of treatment 
with a thyrostatic. 
After one year of anti-thyroid treatment, a statisti-
cally significant decrease in concentrations of OC and 
CTx was observed and this was seen between the sixth 
and the 12th month of treatment. There was no statisti-
cally significant difference in OC and CTx concentra-
tions initially, or after 12 months of treatment with 
levothyroxine, in the group with hypothyroidism. 
The intensity of bone turnover in the group with 
hyperthyroidism was high in the first half of the year of 
anti-thyroid treatment. Despite laboratory-confirmed 
euthyroidism, high concentrations of bone formation and 
bone resorption markers were maintained in blood serum 
in this group, which confirmed persistent enhanced bone 
turnover. Nevertheless, already in the sixth month of anti-
thyroid treatment, a decrease of bone resorption marker 
concentration was noted, which showed a gradual drop 
in the resorption process and the beginning of an im-
provement of bone formation. A decrease in both bone 
formation and bone resorption markers concentration 
were seen from the sixth month of treatment with anti-
thyroid drugs: this confirmed a gradual drop in bone 
metabolism due to normalised concentrations of free 
thyroid hormones and was reflected in the results from 
densitometry after one year of treatment.
The analysis of bone turnover markers concentra-
tion in female patients with hypothyroidism showed no 
statistically significant changes initially, or after 6 and 
12 months of treatment. This was consistent with the 
results from densitometry and confirmed no influence 
of hypothyroidism on bone tissue metabolism. 
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Conclusions
1.  A negative effect on bone metabolism is observed 
only in the group of female patients with hyper-
thyroidism. A decrease in the bone density occurs 
in cortical bone (femoral neck). After one year of 
anti-thyroid treatment, an increase in bone density 
is demonstrated, although it is still lower than in 
the control group, which indicates that correcting 
the hormonal dysfunction does not fully normalise 
bone density. 
2.  Hypothyroidism in premenopausal females does 
not have any influence on bone density. 
3.  The negative impact on bone equilibrium expresses 
first as an increase in markers of bone turnover. This 
permits detection of bone loss at an earlier stage, pre-
ceding the changes observed in densitometry. After 
one year of anti-thyroid treatment, concentrations 
of bone turnover markers decrease in a statistically 
significant way. 
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